Back to results
US 12,758,583 B2Granted
Targetable immune checkpoint for immunotherapy
AssigneeOhio State Innovation Foundation
InventorHaitao Wen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of T cell-based immunotherapy to promote anticancer effector functions.
Claims21
A genetically modified cell comprising a deletion of the Susd2 gene or a fragment thereof, wherein interaction between SUSD2 and IL-2Rα is disrupted.
A method of treating a cancer comprising administering to a subject a genetically modified cell comprising a deletion of the SUSD2 Susd2 gene or a fragment thereof.
Dependencies are inferred from the claim text.